Moreover, pharmacological disruption of the MG53–IRS1 interaction with small‐molecule inhibitors prevents IRS1 degradation, thereby enhancing insulin signaling in muscle cells and improving glucose homeostasis in animal models of insulin resistance [411, 412]. Here, IRS1 is linked to Insulin resistance.